## 1 Introduction  
_Candida_ species are emerging as a major cause of nosocomial infections. Sessile _Candida_ cells exhibit a high resistance to antifungal agents depending on their biochemical, genetic and/or morphological flexibility that enables adaptation to an extensive range of host defense mechanisms. Moreover, the pathogenic activity of _Candida_ spp. is primarily attributed to their high capability to form biofilms on the surfaces of medical devices [1]. Medical device-associated _Candida_ spp. biofilms are refractory to many conventional therapies and can lead to significant complications. Furthermore, _Candida_ spp. infections are more likely to occur and progress more severely in immunosuppressed patients [2]. The most frequently used types of antifungal agents against _Candida_ spp. infections include azoles, polyenes, pyrimidine analogs, and echinocandins [3]. From polyene agents, amphoteric B displays the broadest spectrum and most effective fungicidal activity. Even though amphoteric B is usually preferred among antifungal agents, its use at high doses over an extended time period is associated with side effects such as anemia, hypertension, tremors, and even renal failure [4]. Voriconazole is a new second-generation triazole antifungal agent with a broad-spectrum of activity against opportunistic fungal pathogens, including _Candida_ spp. and _Aspergillus_ spp. [5]. On the other hand, the pharmacokinetic behavior of this triazole is non-linear and presents a narrow therapeutic window, resulting in under-dosage and/or dose-dependent adverse effects [6]. The management of medical device-_Candida_ spp. contaminations faces numerous problems, such as toxicity caused by prolonged treatment with high doses, resistance to conventional therapy, recurrence of infection, and the high treatment costs [7]. In addition, the removal/replacement of an infected medical device may be a challenging because of the patient state and condition [8]. In order to preserve implanted devices, it is therefore imperative to develop new and effective therapeutic strategies for the treatment of _Candida_ spp. biofilms and associated infections, such as associations of two or more antifungals [9], alternative agents (e.g., natural products) or a combination of antifungals and natural compounds [10], as well as more efficient drug delivery systems [11; 12]. Many compounds, extracts, and derivatives of plant origin have been found to be effective and safe antifungal agents, and have a much more acceptable toxicity as compared to commonly used antifungals. Among plant-derived bioactive substances, phenolic plant compounds such as resveratrol and quercetin flavonoids have been shown to inhibit the growth of different pathogenic microorganisms, including fungi [13; 14]. Polymeric thin films have been intensively studied for use in novel drug delivery systems due to their intrinsic properties (e.g., tunable size, form, solubility, stability and degradability, high surface/volume ratio, versatile and easy functionalization, biocompatibility, and biomimetic properties) [15]. Polymeric thin films can be deposited on medical devices by a variety of techniques [16]--matrix-assisted pulsed laser evaporation (MAPLE) [17] has been shown to produce continuous coatings containing various drugs with a high encapsulation efficiency [18]. A core drug is commonly encapsulated within a thin layer of the coating material (e.g., a biodegradable polymer). The coating may be modified in various ways to slow the release rate of the active biomaterial or increase the absorption of the drug into the systemic circulation. The MAPLE approach offers several benefits over conventional encapsulation techniques, including: (a) it is a rapid process that can be completed in several minutes; (b) it is compatible with a variety of materials, enabling thin films to be produced from materials with known biocompatibility properties; (c) it is a dry technique that can be performed using sterile methods; and (d) drug agglomeration can possibly be minimized.